Rocket Pharmaceuticals, Inc.: 10-Q filed 2016-11-09
What Rocket Pharmaceuticals, Inc. reported in its quarterly report filed 2016-11-09 (fiscal Q3 2016): 26 published measures, 68 facts as tagged in accession 0001564590-16-028485.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-11-09
- Fiscal period
- fiscal Q3 2016
- Accession
- 0001564590-16-028485 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Rocket Pharmaceuticals, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 140,139,000 | USD | |
| At 2015-12-31 | 113,321,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 55,085,000 | USD | |
| At 2015-12-31 | 4,508,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 85,054,000 | USD | |
| At 2015-12-31 | 108,813,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 83,004,000 | USD | |
| At 2015-12-31 | 80,042,000 | USD | |
| At 2015-09-30 | 89,248,000 | USD | |
| At 2014-12-31 | 3,618,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -11,128,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -29,880,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -55,961,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -59,810,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | -225,903,000 | USD | |
| At 2015-12-31 | -196,023,000 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,045,000 | USD | |
| At 2015-12-31 | 812,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 1,978,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 1,932,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -10,723,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -29,640,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -5,437,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -12,168,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 138,924,000 | USD | |
| At 2015-12-31 | 112,366,000 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 525,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 525,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 192,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 1,230,000 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 5,944,000 | USD | |
| At 2015-12-31 | 4,141,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,777,000 | USD | |
| At 2015-12-31 | 1,633,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 8,412,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 22,492,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 3,612,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 6,635,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 26,930,730 | shares | |
| At 2015-12-31 | 26,423,394 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 2,000 | USD | |
| At 2015-12-31 | -11,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,418,000 | USD | |
| At 2015-12-31 | 1,074,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 373,000 | USD | |
| At 2015-12-31 | 262,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 170,000 | USD | |
| At 2015-12-31 | 143,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 321,000 | USD | |
| At 2015-12-31 | 367,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 3,716,000 | USD | |
| At 2015-12-31 | 2,508,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,341,000 | USD | |
| At 2015-12-31 | 1,086,000 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -11,128,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -29,880,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -55,961,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -59,940,000 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 2,311,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 7,148,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 1,825,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 5,533,000 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 39,000 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 111,000 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 6,000 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 7,000 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 144,000 | USD | 274 |
| 2015-01-01 to 2015-09-30 | 563,000 | USD | 273 |
Inspect the source
- Entity
- Rocket Pharmaceuticals, Inc. / CIK 0001281895
- Captured
- 2026-09-20T07:48:45.204Z
- SEC response SHA-256
0bcbe84a05b7de7c12edb430923484b522633d995abac19aad70bdfd9e60b3ef
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001281895.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))